<p>Ticlopidine is indicated to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because Ticlopidine&nbsp;is associated with a risk of life-threatening blood dyscrasias including&nbsp;thrombotic thrombocytopenic purpura&nbsp;(TTP), neutropenia/ agranulocytosis and&nbsp;aplastic anemia. Ticlopidine should be reserved for patients who are intolerant or allergic to&nbsp;aspirin&nbsp;therapy&nbsp;or who have failed aspirin therapy.<br />
<br />
Ticlopidine is also indicated as an adjunctive therapy with aspirin to reduce the incidence of subacute stent&nbsp;thrombosis&nbsp;in patients undergoing successful coronary stent&nbsp;implantation</p>